SequelSEC

Zomedica Corp. ZOMDF

Pharmaceutical Preparations · CIK 0001684144 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$36.88M
Fiscal year ended 2026-06-30
Operating income
-$20.75M
Fiscal year ended 2026-06-30
Free cash flow
-$13.67M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$38.30MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.04Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue22.4%24th
SBC / revenue7.7%30th
Current ratio6.78x68th
Revenue YoY growth17.4%64th
Gross margin67.7%43th
Net margin-255.6%45th
FCF margin-56.9%54th
Operating margin-263.4%48th
CapEx / revenue1.8%49th

Zomedica Corp. (ZOMDF) reported revenue of $36.88M and net income of -$18.95M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Zomedica Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Zomedica Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$36.88M
Cost of revenue$12.75M
Gross profit$24.13M
Operating income-$20.75M
Net income-$18.95M
Research & development$5.65M
Weighted-average diluted sharesUnavailable
Pretax income-$19.12M
Income tax expense-$168.00K
Diluted EPSUnavailable
Selling, general & administrative$39.23M
General & administrative$22.86M
Selling & marketing$16.37M

Balance

Zomedica Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$7.19M
Total assets$118.15M
Current assets$57.89M
Total liabilities$10.86M
Current liabilities$9.00M
Total equity incl. NCI$107.28M
Temporary (mezzanine) equityUnavailable
Inventory$6.05M
Accounts receivable$5.67M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.57M

Cash flow

Zomedica Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$13.37M
Capital expenditures$302.00K
Investing cash flow$12.50M
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensation$2.31M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Zomedica Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$13.67M
Gross margin65.4%
Operating margin-56.3%
FCF margin-37.1%
SBC / revenue6.3%
Current ratio6.43x
Revenue YoY growth30.1%
Net margin-51.4%
R&D / revenue15.3%
CapEx / revenue0.8%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZOMDF in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.